AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 23 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Vaccine researchers in the United States have shed new light on the early cytotoxic T-cell response to HIV infection.
"Cytotoxic T-lymphocyte (CTL) responses are thought to control human immunodeficiency virus replication during the acute phase of infection," explained Bianca R. Mothe, University of Wisconsin, and other U.S. colleagues in a multicenter study.
Using a primate model, Mothe and coauthors were able to determine the primary targets of CD8[superscript]+ T lymphocyte activity shortly after HIV exposure.
The researchers examined early CTL activity in a group of rhesus macaques, most of whom expressed the major histocompatibility complex (MHC) class I molecule Mamu-A*01. All animals were exposed to the SIV[subscript]mac239 strain of the simian version of HIV, according to the report.
Cytotoxic T-cell responses in Mamu-A*01[superscript]+ macaques tended to focus on two Mamu-A*01-restricted epitopes, Tat[subscript]28-35SL8 and Gag[subscript]181-189CM9, during the acute infection period. Later in the course of infection, the Gag epitope become the primary target of CTL activity, study data showed.
Early CD8 cell activity targeted the ...